CAJ | 학술논문

目的：评价乙型肝炎肝硬化患者应用拉米夫定联合阿德福韦酯治疗的临床效果。方法：选取2009年1月至2013年1月广州市第一人民医院收治的乙型肝炎肝硬化患者177例，随机分为两组，其中观察组89例，应用拉米夫定联合阿德福韦酯治疗，对照组88例，仅选用拉米夫定治疗，观察并比较两组患者HBV－DNA转阴率、肝功能指标、凝血酶原时间活动度（ PTA）变化、耐药率和不良反应。结果：观察组HBV－DNA、肝功能与PTA变化、耐药率等方面均明显优于对照组，两组比较差异有统计学意义（P＜0．05）。结论：乙型肝炎肝硬化患者应用拉米夫定联合阿德福韦酯治疗的临床效果好，病毒转阴时间短，耐药率低，值得临床推广应用。
목적：평개을형간염간경화환자응용랍미부정연합아덕복위지치료적림상효과。방법：선취2009년1월지2013년1월엄주시제일인민의원수치적을형간염간경화환자177례，수궤분위량조，기중관찰조89례，응용랍미부정연합아덕복위지치료，대조조88례，부선용랍미부정치료，관찰병비교량조환자HBV－DNA전음솔、간공능지표、응혈매원시간활동도（ PTA）변화、내약솔화불량반응。결과：관찰조HBV－DNA、간공능여PTA변화、내약솔등방면균명현우우대조조，량조비교차이유통계학의의（P＜0．05）。결론：을형간염간경화환자응용랍미부정연합아덕복위지치료적림상효과호，병독전음시간단，내약솔저，치득림상추엄응용。
OBJECTIVE:To evaluate the clinical efficacy of lamivudine plus adefovir in patients with hepatitis B and liver cirrhosis.METHODS: 177 patients with liver cirrhosis admitted to Guangzhou Municipal First People's Hospital from January 2009 to January 2013 were randomly divided into two groups, with 89 cases in the observation group treated with lamivudine plus adefovir and 88 cases in the control group treated with adefovir alone.The two groups were compared with regard to rate of negative-returning rate of HBV-DNA, indicators of liver function, prothrombin time activity ( PTA) , drug resistance and adverse drug reactions.RESULTS:The observation group was significantly better than in the control group with regard to negative-returning rate of HBV-DNA, indicators of liver function, prothrombin time activity ( PTA) and drug resistance etc, with significant differences noted between the two groups ( P<0.05 ) .CONCLUSION: Treatment of patients with hepatitis B and liver cirrhosis using lamivudine plus adefovir resulted in noticeable efficacy, short virus negative-returning time and low drug resistance, which thus is worthy of clinical recommendation.